Global Chronic Kidney Disease Drugs Market, by Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), B-Blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, and others), by Route of Administration (Oral, Subcutaneous, Intravenous), by Patient Type (Dialysis, Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 13,220.0 Million in 2022 and is expected to exhibit a CAGR of 4.5% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Global chronic kidney disease drugs market is expected to witness significant growth over the forecast period, owing to factors such as drug approvals, collaborations, partnerships and acquisitions, and product launches by the key players. For instance, in November 2021, Zydus Cadila, a global pharmaceutical company announced that it is seeking the Drug Controller General of India (DCGI) nod for a drug that can be used as an oral alternative to treat anaemia in patients with chronic kidney disease.
Moreover, in November 2021, GlaxoSmithKline plc., announced positive results from the Phase III ASCEND program for daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), during a presentation at the American Society of Nephrology’s Kidney Week 2021. The positive primary efficacy and safety results confirm the potential for daprodustat to be a new oral treatment for patients with anaemia due to chronic kidney disease (CKD) in both non-dialysis and dialysis settings.
Global Chronic Kidney Disease Drugs Market– Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020. With dynamically surging cases of COVID-19, the risk for patients acquiring chronic kidney diseases is also increasing.
According to a study conducted by the researchers at Mount Sinai Health System, New York City, U.S., an epidemic of post-COVID-19 kidney disease might occur after the COVID-19 pandemic.
The researchers at the Mount Sinai Health System conducted a retrospective observational study of nearly 3,993 patients hospitalized in U.S., due to COVID-19 from February 27, to May 30, 2020 and reviewed the data from electronic health records of patients older than 18 years. The statistics from the study revealed that around 35% of COVID-19 patients developed acute kidney injury (AKI) which was not recovered even during hospital discharge.
Moreover, according to the National Kidney Foundation, a study found that patients hospitalized during March 11 and April 26, 2020, due to COVID-19 were twice as likely to develop acute kidney injury (AKI) as compared to non-COVID patients who developed AKI during the same time period in 2019.
Moreover, increasing inorganic growth strategies such partnerships by key market players is expected to drive the growth of global chronic kidney disease market. For instance, in October 2020, Fresenius Medical Care North America (FMCNA), the nation's leading renal care company, announced an innovative partnership with Livongo Health, Inc., the leading Applied Health Signals Company, to improve the lives and outcomes of people with late-stage chronic kidney disease (CKD). The new partnership enables Fresenius Health Partners, a division of FMCNA, to better deliver targeted, real-time care coordination services through Livongo Whole Person for CKD.
Global Chronic Kidney Disease Drugs Market: Key Developments
Increasing government initiatives for setting up better healthcare infrastructure in the region, which is expected to drive the growth of global chronic kidney disease drugs market over the forecast period. For instance, in June 2018, the government of Mexico opened the largest government-owned renal care center in Pampanga located at the Mexico Community Hospital.
Browse 32 Market Data Tables and 26 Figures spread through 178 Pages and in-depth TOC on “Global Chronic Kidney Disease Drugs Market”- Forecast to 2030, Global Chronic Kidney Disease Drugs Market, by Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), B-Blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, and others), by Route of Administration (Oral, Subcutaneous, Intravenous), by Patient Type (Dialysis, Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/chronic-kidney-disease-drugs-market-1713
Moreover, increasing adoption of inorganic strategies such as signing marketing agreements by key players in market is expected to drive the global chronic kidney disease drugs market growth over the forecast period. For instance, in April 2021, Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, announced that Triferic AVNU (ferric pyrophosphate citrate injection) received a Notice of Compliance (marketing approval) from Health Canada for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease.
Key Takeaways of the Global Chronic Kidney Disease Drugs Market:
- Global chronic kidney disease drugs market is expected to exhibit a CAGR of 4.5% during the forecast period due to increasing research and development activities for development of chronic obstructive pulmonary disease treatment. For instance, in June 2021, Novartis announced Phase II primary endpoint data showing investigational iptacopan (LNP023) – a first-in-class, oral, targeted factor B inhibitor – reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating with progression to kidney failure, and showed promise in stabilizing kidney function in patients with IgA nephropathy (IgAN).
- Increasing inorganic growth strategies such as collaborations and agreements is expected to drive the growth of global chronic kidney disease drugs market. For instance, in August 2020, AstraZeneca Plc. entered into a collaboration with Renalytix AI plc., a commercial-stage artificial intelligence-enabled in vitro diagnostics company to develop and launch precision medicine strategies for cardiovascular, renal, and metabolic diseases.
- Among regions, North America is estimated to account for the largest market share in the global chronic kidney disease drugs market over the forecast period, owing to increasing prevalence of the chronic obstructive pulmonary disease in the region. For instance, in November 2019, according to the data published by the Center for Disease Control and Prevention, in the U.S., age-adjusted death rates for COPD were significantly lower in 2019 compared with 2017 among U.S. men (57.0 per 100,000 in 1999 and 40.5 per 100,000 in 2019) and among U.S. women (35.3 per 100,000 in 1999 and 34.3 per 100,000 in 2019). According to World Health Organization, asthma affected an estimated 262 million people in 2019 (1) and caused 455, 000 deaths globally.
- Major players operating in the Global Chronic Kidney Disease Drugs Market include Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd.
